The drug has gone through 12 clinical trials in more than 1,400 subjects already, showing that it knocks down serum bile acid levels safely...Also in the pipeline: Lumena has licensed the patent rights and a package of clinical and non-clinical data for LUM002, another inhibitor of ASBT, also previously in development at the Phase I stage as a cholesterol-lowering agent by Paris-based Sanofi SA...Lumena plans to complete the Phase I clinical program of LUM002 in healthy volunteers later this year

The company's "exceptional team" and its potential to obtain rapid clinical efficacy data were two attractive attributes, Rafaèle Tordjman, managing partner at Sofinnova Partners, told BioWorld Today...The company plans to use the funds to move its lead program into clinical trials and to advance a second discovery program...On Tuesday, shares of StemCells (NASDAQ:STEM) gained 7 cents, closing at $1.68.

Under the terms, MidCap will receive warrants to purchase an aggregate of 588,235 shares of Anthera's common stock at an exercise price of 68 cents each...Canbex, a spinout of University College London, has said it expects to start clinical testing this year

UCB also picked up clinical development and commercialization costs. (See BioWorld Today, May 11, 2006.) In 2009, the companies reported results from a Phase IIb dosing study of the drug showing a 24.9 percent treatment advantage over placebo in systemic lupus erythematosus (SLE) patients...The funding will support the advancement of Blaze's Tumor Paint product candidate, BLZ-100, into clinical development for use in surgery in multiple solid tumor types. (See BioWorld Today, June 11, 2012...Oxygen

The warrants have an exercise price of $3.94 per warrant and are exercisable for a term of five years...The transaction is expected to close on Feb. 19.

The warrants are exercisable immediately upon issuance, have a four-year term and an exercise price of $3 per share...The net proceeds will be used for working capital and general corporate purposes, including the continuation of the Abili-T clinical study, Opexa's ongoing Phase IIb trial of Tcelna in secondary progressive multiple sclerosis patients

Anthera's Phase IIb study, PEARL-SC, missed its primary efficacy endpoint of clinical improvement at 24 weeks in the Systemic Lupus Erythematosus Responder Index...The primary efficacy endpoint will be clinical improvement in the Systemic Lupus Erythematosus Responder Index (SRI-8...Net proceeds are expected to support general corporate purposes, including working capital, R&D, clinical trials and capital expenditures

The warrants have an exercise price of $1.24 per share, a five-year term and are exercisable for an aggregate of 243,750 shares of the company's common stock.

For us it was a very good clinical proof of concept," Mark Krul, the company's other joint managing director told BioWorld Today...The investors will also receive 100 percent warrant coverage at an exercise price of 12 cents per share...The company intends to use the proceeds to continue the clinical development of its immunotherapy platform, a personalized combination of cancer cell vaccination and "killer" T-cell treatment

Trevi Therapeutics Inc., of New Haven, Conn., closed a $10 million Series A financing to advance the clinical development of T111 in the lead indication of uremic pruritis...Proceeds are expected to advance T111, an oral, extended-release opioid, into clinical development, with an efficacy study expected to begin in the first quarter of 2014.

Data also indicated rapid onset of activity, with clinical activity reported for 16 of 19 responders occurring within the first two cycles of treatment...OncoSec plans to use the proceeds to fund clinical trials and research and development and for other corporate purposes...The company plans to use the proceeds to fund research and development, clinical trials and for other corporate purposes.

The company plans to use proceeds to expand clinical development of its dismutase mimetics, small-molecule mimics of critical enzymes in the oxygen metabolic pathways designed to overcome limitations of prior approaches to controlling superoxide and its harmful roles in human disease...In addition, unit holders were issued one warrant for two shares of stock purchased at an exercise price of 50 cents per share for five years

The warrants, to be issued separately, are exercisable upon issuance and have a one-year term and an exercise price of $1.50 per share...It also plans to start a Phase IIa trial with RHB-104 for the treatment of multiple sclerosis in January 2013.

The Series D enables Zafgen to move clinical and regulatory activities forward without the distraction of additional fundraising, Hurwitz added...In addition, the investors will receive warrants for 26.25 million shares of common stock, with an exercise price of 40 cents per share, exercisable no less than six months after the transaction, with a term of four years from issuance...Proceeds will support a Phase III trial of Multikine (leukocyte interleukin, injection).

The stock is convertible into common stock at 50 cents per share, and the units provided for 100 percent warrant coverage with an exercise price of 50 cents per share and a term of six years...Puma is working on neratinib, an oral, irreversible kinase inhibitor for HER2-posistive metastatic breast cancer. (See BioWorld Today, Oct. 22, 2012.)

The warrants are exercisable for five years at an exercise price of $3.45 per share...Proceeds would be used for R&D activities, clinical trials, investment in capital equipment and for working capital and other general corporate purposes

Proceeds will be used to fund ACT's clinical activities, including its three ongoing Phase I/II trials for forms of macular degeneration, for development of its other clinical activities and for general corporate purposes...Pluristem Therapeutics Inc., of Haifa, Israel, closed its previously announced firm commitment underwritten public offering of 8 million units at $4 each, with each unit consisting of a share of the company's stock and a warrant to purchase a third of a share, at an exercise

Proceeds will support Coronado's clinical programs for Trichuris suis ova (CNDO-201), a biologic therapy for autoimmune disease, and CNDO-109, a biologic therapy for acute myeloid leukemia and solid tumors...In addition, Coronado issued a warrant to purchase 73,009 shares of Coronado common stock at an exercise price of $5.65 per share

Prior to that, the firm's stock had traded below $1 since late June on disappointing top-line data showing that blisibimod failed to meet the primary efficacy endpoint, defined as clinical improvement at 24 weeks in the Systemic Lupus Erythematosus Responder Index (SRI) for the pooled dose groups...Gross proceeds totaled about $5.7 million and net proceeds of about $4.9 million will be used for clinical trials, R&D, working capital needs, capital expenditures and other general corporate purposes